Pretargeted Radioimmunotherapy using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

PURPOSE: Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However, “endogenous” biotin can interfere with the effectiveness of this approach by blocking binding of radiolabeled biot...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Park, Steven I., Shenoi, Jaideep, Frayo, Shani M., Hamlin, Donald K., Lin, Yukang, Wilbur, D. Scott, Stayton, Patrick S., Orgun, Nural, Hylarides, Mark, Buchegger, Franz, Kenoyer, Aimee L., Axtman, Amanda, Gopal, Ajay K., Green, Damian J., Pagel, John M., Press, Oliver W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3229652/
https://ncbi.nlm.nih.gov/pubmed/21976541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1204
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi